From: Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer
No. of patients (%)
Cycle of DCS
1
29
(96.7)
2
25
(83.3)
S-1 administration period (month)
3
28
(93.3)
6
27
(90.0)
9
23
(76.7)
12
18
(60.0)